INAB IN8BIO INC

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.

A high-definition video webcast of the presentation will be available the following day on the Company's website /news-events/events-presentations, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: and on Channelchek the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit  

Investors and Corporate Contacts:

Glenn Schulman, PharmD, MPH

203.494.7411

Patrick McCall, CFO

IN8bio, Inc

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
02/12/2024

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 ...

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients 100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this to...

21h / 1m 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at Biotech Showcase 2025 in San Francisco

IN8bio to Present at Biotech Showcase 2025 in San Francisco NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below. Biotech Showcase, January 13 - 15, 2025 Panel: The Battle Against Cancer: The Arma...

January 6, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investig...

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100’s long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration ...

December 10, 2024 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging ...

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET. A high-definition video webcast of the presentation will be available the following day on the Company's website /news-events/events-presentati...

December 2, 2024 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-20...

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome. Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following treatment wit...

November 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch